The Patent Fight That Could Derail the World's Best-Selling Drug

Merck, apparently, tried to go around the tollbooth.

The Lifecycle Management Playbook (and Why It's Stalling)

Merck's strategy for Keytruda is a textbook example of lifecycle management, the pharmaceutical art of keeping a blockbuster profitable even after key patents expire. The playbook goes like this: develop a better version of your drug (faster, easier, more convenient), secure new patents on that version, and migrate patients before generic competitors arrive.

Keytruda QLEX was supposed to be the better version. Instead of 30 minutes hooked up to an IV, patients could get their dose in roughly one to two minutes via a subcutaneous injection. Faster for patients, easier for clinics, and wrapped in a fresh patent estate.

The Dutch ruling doesn't kill Keytruda in Europe. The IV version remains fully available and legal. But it does something arguably worse for Merck's long-term plan: it blocks the very product designed to carry the franchise past its patent cliff. If Merck can't roll out the subcutaneous version in key European markets, it can't migrate patients away from the IV formulation before biosimilars arrive.

It's like trying to move into your new house before the old lease expires, only to find out the locks have been changed.

Halozyme's Legal Blitz

This Dutch ruling isn't an isolated skirmish. It's part of a coordinated multi-front legal campaign by Halozyme that spans continents.

The company sued Merck in New Jersey in April 2025, alleging that Keytruda QLEX infringed 15 separate patents. That's not a sniper shot; that's a carpet bombing. Merck fired back by challenging multiple Halozyme patents at the U.S. Patent Trial and Appeal Board.

Meanwhile, in Europe, Halozyme won a preliminary injunction in Germany in December 2025. The Dutch ruling in October 2026 adds another major win. The company also pursued action in the UK, though at least one of the patents at issue there was narrowed during proceedings.

The pattern is clear. Halozyme approached Merck about licensing before the lawsuits began, essentially saying, "We'd prefer to make a deal, but we'll see you in court if we have to." Merck declined. Now Halozyme is proving, jurisdiction by jurisdiction, that its patents hold up.

What Wall Street Thinks

Analysts aren't panicking about Merck's overall business. About 60% of Keytruda sales come from the United States, where the Dutch ruling has no direct impact. The IV version continues to generate massive revenue globally. And the broader oncology franchise remains intact.

But the strategic implications are real. The ruling validates Halozyme's patent position in Europe, giving the smaller company significantly more leverage in any future licensing or settlement talks. If Halozyme's patents keep winning in court, Merck may eventually have to come to the table and negotiate a royalty deal, exactly the outcome Halozyme has been engineering from the start.

For Merck, the risk isn't that Keytruda disappears. It's that the bridge to the post-patent-cliff era gets narrower. Every market where the subcutaneous version is blocked is a market where the lifecycle management strategy stalls. And with the 2028 IV patent expiration approaching fast, time is not Merck's friend.

Merck has said it disagrees with the ruling and believes Halozyme's patent is invalid. The company is evaluating next steps, which likely means appeals. But appealing takes time, and the injunction is in effect now.

The Bigger Picture

This fight isn't just about Merck and Halozyme. It's a signal to every pharma company betting on subcutaneous reformulations as a lifecycle strategy. The delivery technology isn't free, and companies like Halozyme are increasingly willing to enforce their intellectual property across multiple jurisdictions simultaneously.

Halozyme's MDASE patent portfolio (the one at issue in the Dutch case) covers roughly 100 patents and pending applications worldwide, spanning composition, manufacturing, and method-of-use claims. That's a lot of legal surface area for potential infringers to navigate.

The subcutaneous delivery space is booming precisely because patients and payers prefer convenience. But convenience has a price, and Halozyme is making sure everyone pays it.

For Merck, the clock is ticking. The world's best-selling drug needs a succession plan, and that plan just hit a major roadblock in Europe. Whether this ends in a licensing deal, a settlement, or years of further litigation, one thing is certain: Halozyme has proven it can play hardball with a company fifty times its size.

And right now, the scoreboard favors the little guy.

Why Telix Just Paid $2.35 Billion for a Factory

Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies, and the real story isn't the pipeline. It's a high-stakes bet on controlling the fragile supply chain that the entire radiopharmaceutical industry depends on.